SAB Biotherapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

SAB Biotherapeutics şirketinin kazançları yıllık ortalama -19.7% oranında azalırken, Biotechs sektörünün kazançları yıllık 33.8% oranında artan oldu. Gelirler yıllık ortalama 72.9% oranında azalan oldu.

Anahtar bilgiler

-19.73%

Kazanç büyüme oranı

-16.86%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.04%
Gelir büyüme oranı	-72.94%
Özkaynak getirisi	-0.18%
Net Marj	n/a
Son Kazanç Güncellemesi	31 Mar 2026

Yakın geçmiş performans güncellemeleri

Recent updates

Analiz Makalesi • Nov 22

We Think SAB Biotherapeutics (NASDAQ:SABS) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Analiz Makalesi • Sep 22

SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analiz Makalesi • Apr 17

Improved Revenues Required Before SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock's 42% Jump Looks Justified

SAB Biotherapeutics, Inc. ( NASDAQ:SABS ) shareholders are no doubt pleased to see that the share price has bounced 42...

Analiz Makalesi • Jan 20

Analysts Are Betting On SAB Biotherapeutics, Inc. (NASDAQ:SABS) With A Big Upgrade This Week

SAB Biotherapeutics, Inc. ( NASDAQ:SABS ) shareholders will have a reason to smile today, with the analysts making...

Analiz Makalesi • Nov 19

Need To Know: Analysts Are Much More Bullish On SAB Biotherapeutics, Inc. (NASDAQ:SABS) Revenues

Shareholders in SAB Biotherapeutics, Inc. ( NASDAQ:SABS ) may be thrilled to learn that the analysts have just...

Analiz Makalesi • Nov 18

Earnings Beat: SAB Biotherapeutics, Inc. (NASDAQ:SABS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

SAB Biotherapeutics, Inc. ( NASDAQ:SABS ) missed earnings with its latest third-quarter results, disappointing...

Seeking Alpha • Sep 28

SAB Bio rises as H1N1 influenza and COVID-19 treatments show efficacy in trial

SAB Biotherapeutics (NASDAQ:SABS) is trading 5.6% higher after the company said its fully-human polyclonal antibody platform maintains efficacy against multiple variants of several highly mutating viruses. A Phase 2a challenge trial showed SAB-176 reduced the viral load in subjects exposed to H1N1 influenza virus and improved symptoms by day four and shortened the timeframe for viral shedding. Another study showed that SAB-185 COVID-19 polyclonal antibody therapeutic candidate was effective in animal models against the majority of known SARS-CoV2 variants.

Analiz Makalesi • Aug 12

What Does The Future Hold For SAB Biotherapeutics, Inc. (NASDAQ:SABS)? These Analysts Have Been Cutting Their Estimates

The latest analyst coverage could presage a bad day for SAB Biotherapeutics, Inc. ( NASDAQ:SABS ), with the analysts...

Seeking Alpha • Aug 10

SAB Biotherapeutics GAAP EPS of -$0.11 beats by $0.03

SAB Biotherapeutics press release (NASDAQ:SABS): Q2 GAAP EPS of -$0.11 beats by $0.03. Cash and cash equivalents were $16.6 million as of June 30, 2022, compared to $22.4 million on March 31, 2022, which was driven primarily by $0.7 million in further capital expansion and SAB’s second quarter cash operating loss of $5.1 million. Financial Guidance: Based on its current operating plans, SAB expects that its existing business plan, cash and cash equivalents, and anticipated cash flows as of June 30, 2022, will be sufficient to fund its operating expenses and capital expenditure requirements for the twelve months following the date our quarterly report on Form 10-Q was made available for issuance.

Analiz Makalesi • Apr 06

Downgrade: Here's How Analysts See SAB Biotherapeutics, Inc. (NASDAQ:SABS) Performing In The Near Term

Market forces rained on the parade of SAB Biotherapeutics, Inc. ( NASDAQ:SABS ) shareholders today, when the analysts...

Gelir ve Gider Dağılımı

SAB Biotherapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqCM:SABS Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
31 Mar 26	0	-9	19	6
31 Dec 25	0	4	16	0
30 Sep 25	0	-4	12	1
30 Jun 25	0	-20	12	14
31 Mar 25	0	-34	13	0
31 Dec 24	1	-34	15	0
30 Sep 24	2	-46	26	22
30 Jun 24	3	-40	25	0
31 Mar 24	3	-40	25	0
31 Dec 23	2	-42	24	0
30 Sep 23	4	-27	12	0
30 Jun 23	6	-29	13	0
31 Mar 23	13	-27	15	0
31 Dec 22	24	-19	16	0
30 Sep 22	33	-22	21	0
30 Jun 22	44	-19	21	0
31 Mar 22	56	-18	19	0
31 Dec 21	61	-17	17	0
30 Sep 21	76	7	10	-11
30 Jun 21	78	17	10	0
31 Mar 21	66	21	9	0
31 Dec 20	55	20	7	0
31 Dec 19	3	-9	4	0

Kaliteli Kazançlar: SABS şu anda kârlı değil.

Büyüyen Kar Marjı: SABS şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: SABS kârlı değildir ve zararlar son 5 yılda yılda 19.7% oranında artmıştır.

Büyüme Hızlandırma: SABS 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: SABS kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 43% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: SABS hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -0.18% ) sahiptir.

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/22 08:55
Gün Sonu Hisse Fiyatı	2026/05/22 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

SAB Biotherapeutics, Inc. 11 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Kumaraguru Raja	Brookline Capital Markets
Keay Nakae	Chardan Capital Markets, LLC
Samantha Lynn Semenkow	Citigroup Inc

SAB Biotherapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

SAB Biotherapeutics, Inc. to Report Q1, 2026 Results on May 12, 2026

First half 2025 earnings released: US$1.65 loss per share (vs US$1.34 loss in 1H 2024)

First quarter 2025 earnings released: US$0.56 loss per share (vs US$0.54 loss in 1Q 2024)

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2024 earnings released: US$1.12 loss per share (vs US$0.97 loss in 3Q 2023)

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

New major risk - Revenue and earnings growth

New minor risk - Profitability

SAB Biotherapeutics, Inc. to Report Q1, 2026 Results on May 12, 2026

Sab Biotherapeutics, Inc. Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes

Investor sentiment deteriorates as stock falls 19%

SAB Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $84.999728 million.

SAB Biotherapeutics Inc Announces Additional Phase 1 Data for SAB 142 in Adult Patients with Established Autoimmune Type 1 Diabetes

SAB Biotherapeutics, Inc. Announces Board Changes ,Effective January 7, 2026

No longer forecast to breakeven

SAB Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

First Patient Dosed in SAB Biotherapeutics, Inc.'S Safeguard Clinical Trial of Sab-142 for the Treatment of Stage 3 T1d

New minor risk - Profitability

SAB Biotherapeutics, Inc. Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D

Sab Biotherapeutics, Inc. to Present Data Showcasing Progress in the Development of SAB-142 At the Asian Conference on Innovative Therapies for Diabetes Management

We Think SAB Biotherapeutics (NASDAQ:SABS) Can Afford To Drive Business Growth

Forecast to breakeven in 2025

New major risk - Shareholder dilution

SAB Biotherapeutics, Inc. Highlights Data in Multiple Presentations at EASD

Price target decreased by 16% to US$9.60

First half 2025 earnings released: US$1.65 loss per share (vs US$1.34 loss in 1H 2024)

SAB Biotherapeutics, Inc. announced that it has received $175 million in funding from a group of investors

SAB Biotherapeutics, Inc. announced that it expects to receive $175 million in funding from a group of investors

SAB Biotherapeutics, Inc., Annual General Meeting, Jul 17, 2025

First quarter 2025 earnings released: US$0.56 loss per share (vs US$0.54 loss in 1Q 2024)

Consensus revenue estimates decrease by 50%, EPS upgraded

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

Third quarter 2024 earnings released: US$1.12 loss per share (vs US$0.97 loss in 3Q 2023)

SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely

Price target decreased by 35% to US$13.00

Consensus revenue estimates increase by 30%

Sab Bio Announces Founding of Clinical Advisory Board to Guide the Development of Sab-142 for Type 1 Diabetes

SAB Biotherapeutics, Inc. Appoints Lucy to as Chief Financial Officer, Effective August 12, 2024

SAB Biotherapeutics, Inc., Annual General Meeting, Jun 27, 2024

FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics

SAB Biotherapeutics, Inc. announced delayed 10-Q filing

SAB Biotherapeutics, Inc. Appoints Jay Skyler, Md, to the Board of Directors

SAB Biotherapeutics, Inc. Provides SAB-142 Trial Update

Price target increased by 25% to US$25.00

New major risk - Revenue and earnings growth

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

SAB Biotherapeutics, Inc. Announces CEO Changes

SAB Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

New major risk - Shareholder dilution

SAB Biotherapeutics Announces Commencement of the Human Phase 1 Clinical Trial with Sab-142

SAB Biotherapeutics, Inc. Appoints Katie Ellias to the Board of Directors

Consensus revenue estimates increase by 61%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 22% to US$2.50

SAB Biotherapeutics, Inc. Appoints Michael G. King Jr. as Chief Financial Officer

SAB Biotherapeutics Appoints Andrew Moin to Board of Directors

Consensus revenue estimates decrease by 51%, EPS upgraded

Consensus revenue estimates decrease by 81%, EPS upgraded

SAB Biotherapeutics, Inc., Annual General Meeting, Jun 29, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

SAB Biotherapeutics, Inc. Announces First Publication of Promising Nonclinical Data for Sab-183 Against Pneumonic Plague in the Journal Antibodies

SAB Biotherapeutics Announces Progress on U.S. FDA's Phased Review of Company's DiversitAb Platform

SAB Biotherapeutics, Inc. Presents Positive Phase 1 and 2a Data for SAB-176 Influenza Immunotherapy at ISIRV-AVG Conference

Consensus revenue estimates decrease by 56%, EPS upgraded

Improved Revenues Required Before SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock's 42% Jump Looks Justified

Full year 2022 earnings released: US$0.43 loss per share (vs US$0.63 loss in FY 2021)

Analysts Are Betting On SAB Biotherapeutics, Inc. (NASDAQ:SABS) With A Big Upgrade This Week

SAB Biotherapeutics, Inc. Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes

SAB Biotherapeutics Novel Diversitab(Tm) Platform Proven to Develop Anti-Idiotype Antibodies to Help Treat Autoimmune Diseases

SAB Biotherapeutics, Inc. announced that it has received $7.884 million in funding

SAB Biotherapeutics Inc. Initiates IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes

Need To Know: Analysts Are Much More Bullish On SAB Biotherapeutics, Inc. (NASDAQ:SABS) Revenues